Table 4.
Multivariate analysis of variables for OS and PFS in training and validation cohorts when SII - EBV DNA was incorporated
| Variables | OS | PFS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Training cohort | ||||
| SII - EBV DNA | ||||
| Low SII+negative EBV DNA | Ref | Ref | Ref | Ref |
| Low SII+positive EBV DNA vs Low SII+negative EBV DNA | 1.500 (0.235-9.588) | 0.668 | 1.333 (0.275-6.457) | 0.721 |
| High SII+negative EBV DNA vs Low SII+negative EBV DNA | 2.435 (0.475-12.489) | 0.286 | 4.079 (1.082-15.380) | 0.038* |
| High SII+positive EBV DNA vs Low SII+negative EBV DNA | 7.869 (1.766-35.052) | 0.007* | 7.750 (2.208-27.205) | 0.001* |
| Validation cohort | ||||
| SII - EBV DNA | ||||
| Low SII+negative EBV DNA | Ref | Ref | Ref | Ref |
| Low SII+positive EBV DNA vs Low SII+negative EBV DNA | 2.353 (0.196-28.266) | 0.500 | 1.143 (0.436-10.536) | 0.348 |
| High SII+negative EBV DNA vs Low SII+negative EBV DNA | 3.448 (0.374-31.792) | 0.275 | 3.556 (0.355-6.821) | 0.558 |
| High SII+positive EBV DNA vs Low SII+negative EBV DNA | 4.000 (1.423-10.188) | 0.022* | 7.714 (1.888-31.526) | 0.004* |
Note: *statistically significant.
SII: systemic immune-inflammation index; EBV DNA: Epstein-Barr virus DNA; OS: overall survival; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval.